Abstract
Background Although arteriovenous fistulas (AVF) are widely accepted as the gold standard form of dialysis access for hemodialysis patients, high AVF flow may impose significant hemodynamic stress, potentially contributing to adverse cardiovascular events, including heart failure (HF). Understanding this relationship is crucial for improving patient care.
Aim To describe the relationship between AVF flow and cardiac outcomes.
Methods A comprehensive search of the PubMed, EMBASE, and Cochrane databases was used to identify observational studies and randomized controlled trials reporting an effect of AVF flow on cardiac outcomes (clinical, echocardiographic, and biomarker). Due to study heterogeneity, meta-analysis was not feasible. Synthesis without meta-analysis (SWiM) was performed using vote counting of direction of effect as the primary outcome.
Results Higher AVF flow rates were consistently associated with increased incidence of HF and worsening HF symptoms. Cardiac imaging revealed left ventricular dilation and reduced left ventricular ejection fraction in patients with high-flow AVFs. Elevated biomarkers, such as natriuretic peptides, corroborated the adverse cardiovascular effects of high AVF flow.
Conclusions This systematic review and synthesis without meta-analysis showed a positive relationship between AVF flow and clinical, echocardiographic, and biomarker cardiovascular outcomes, but an inverse relationship between AVF flow and mortality. The methodological heterogeneity of studies highlights the need for well-designed prospective research with standardised definitions of high flow AVFs and measures for reporting of cardiovascular outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. NS was supported by an Australian Government Research Training Program (RTP) Scholarship, a Royal Australasian College of Physicians Jacquot Research Entry Scholarship, and a Baxter Family Postgraduate Scholarship. None of the researchers involved in this project had any financial, commercial, legal, or professional relationships with other organizations that could influence the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All data used in this systematic review are publicly available from previously published studies. Citations and references for the included studies are provided within the manuscript and supplementary materials. Template data collection forms, data extracted from included studies, and data used for all analyses will be made available by the corresponding author upon request.
